ArticleGastroenterology report2025
Global, regional, and national burden of inflammatory bowel disease from 1990 to 2021: findings from the Global Burden of Disease 2021.
Article in Gastroenterology report, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Astaxanthin-Turmeric-Honeysuckle Extract Combination Attenuates DSS-Induced Colitis with Preservation of the Epithelial Barrier and Reduced NLRP3/Caspase-1/GSDMD Signaling.Molecules (Basel, Switzerland) · 2026Article
- CCR5Δ32 Polymorphism and Inflammatory Bowel Disease: A Case-Control and Genotype-Phenotype Study in a Polish Population.International journal of molecular sciences · 2026Article
- Towards Precision Medicine in Inflammatory Bowel Diseases: Pharmacogenetic Predictors of Ustekinumab Effectiveness and Persistence.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Global burden of inflammatory bowel disease in Asia, 1990-2023: A global burden of disease study 2023.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2026Article
- Watercress Extract Reduces Experimental Colitis by Modulating Inflammation and Regulating the Gut Microbiota.Nutrients · 2026Article
- Global trends in the burden of inflammatory bowel disease from 1990 to 2021: socioeconomic and sex-specific disparities with exploratory mendelian randomization analyses.Clinical and experimental medicine · 2026Article
- Factors Associated with Frailty in Patients with Active Inflammatory Bowel Disease: A Single-Center Observational Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Evaluation of the Intestinal Anti-Inflammatory Property ofPharmaceutics · 2026Article
- Crohn's Disease and Axial Spondyloarthritis: From Systemic Inflammation to Amyloidosis.Journal of clinical medicine · 2026Article
- Anti-inflammatory effects of oridonin on anExperimental and therapeutic medicine · 2026Article
- The Impact of Informal Caregiving on Patient-Reported Outcomes, Psychological Well-Being and Quality of Life in Inflammatory Bowel Disease: A Systematic Review.Nursing reports (Pavia, Italy) · 2026Review
- Dysfunction of mitochondria in intestinal epithelial cells: a key player in the pathogenesis of inflammatory bowel diseases.Gastroenterology report · 2026Review
- Acupoint Catgut Embedding Ameliorates Ulcerative Colitis in Association with Modulation of cGAS-STING Signaling and M1-Like/M2-Like Macrophage Markers.Journal of inflammation research · 2026Article
- Drug-associated inflammatory bowel disease: a real-world pharmacovigilance study using the FAERS and JADER databases.Frontiers in immunology · 2026Article
- Vedolizumab in biologic-naïve ulcerative colitis: a multicenter real-world evaluation of clinical benefits and exploratory inflammatory indices.Frontiers in medicine · 2026Article
- The impact of dietary interventions on quality of life in adults with inflammatory bowel disease: a narrative review.Journal of nutritional science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammatory bowel disease (IBD) imposes a significant economic and social burden. We aimed to assess the burden of IBD globally, regionally, and nationally. Methods: The incidence, mortality, prevalence, and disability-adjusted life year were obtained from Global Burden of Disease 2021. Estimated annual percentage change, average annual percent change, and age-period-cohort model were used to access trends. Associations between age-standardized rate (ASR) and socio-demographic index were explored. Predictions were made using Bayesian age-period-cohort model and Nordpred. Results: In 2021, IBD affected 3.8 million people, with ASR of incidence and death of 4.4 and 0.5. The global ASR of incidence increased from 1990 to 2021, while ASR of death, prevalence, and disability-adjusted life year decreased. The age-standardized death rate (ASDR) did not show a significant increase from 2019 to 2021 in most regions and countries. High-incidence regions, such as Western Europe, continued to face significant burdens. East Asian, especially China, was experiencing a sharp increase in incidence. ASR of incidence and death increased with rising socio-demographic index. By 2035, the ASR of incidence and death of IBD will gradually decline. Conclusion: The global burden of IBD remains severe with changing epidemiological trends. Reducing the burden requires changes in public health policies, disease prevention, and healthcare services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.